Human TNFRSF17 Protein, mFc Tag_天津卡梅德科技发展有限公司

>>

>>

>>

>

Human TNFRSF17 Protein, mFc Tag

Human TNFRSF17 Protein, mFc Tag

产品编号

KMP2432

别名

B细胞成熟抗原, CD269, BCMA

规格

50ug
100ug
200ug

DATASHEET MSDS

立即询价加入询价列表大包装定制

产品介绍

Catalog Number	KMP2432
Alias	B细胞成熟抗原, CD269, BCMA
Size	50ug, 100ug, 200ug
Product Description	The Human TNFRSF17 Protein(KMP2432) is produced in HEK293 Cells and the target gene encoding Met1-Ala54 is expressed with a mFc tag at the C-terminus.
Molecular Name	TNFRSF17
Product Introduction	TNFRSF17（BCMA）：TNF受体超家族跨膜蛋白，主要表达于浆细胞，参与B细胞成熟调控。
Molecular Weight	5.9 kDa
Expression System	HEK293 Cells
Species	Human
Purity	>90%
SDS-PAGE
Purification	Affinity Purification
Uniprot ID	H3BMB5#structure
Storage Condition	Aliquot and store at -20℃ to -80℃. Avoid repeated freezing and thawing cycles.
Formulation	PBS, pH7.4
Shipping Condition	In general, the proteins are provided as lyophilized powder which are shipped at ambient temperature. They are shipped out in dry ice if supplied in liquid form.
Background	B cell maturation antigen(BCMA) is a member of the TNF receptor superfamily. It has been designated TNFRSF17. Mouse BCMA is a 185 amino acid(aa) protein consisting of a 49 aa extracellular domain, a 23 aa transmembrane domain, and a 113 aa intracellular domain. BCMA is a type III membrane protein containing one extracellular cysteine rich domain. Within the TNFRSF, it shares the highest homology with TACI. BCMA and TACI have both been shown to bind to APRIL and BAFF, members of the TNF ligand superfamily. BCMA expression has been found in immune organs and mature B cell lines. Although some expression has been observed at the cell surface, BCMA appears to be localized to the Golgi compartment. The binding of BCMA to APRIL or BAFF has been shown to stimulate IgM production in peripheral blood B cells and increase the survival of cultured B cells. This data suggests that BCMA may play an important role in B cell development,function and regulation.
Endotoxin	<1.0 EU/ug determined by the LAL method
Product Declaration	该产品仅供科研使用，不可直接用于人体或注射。

FAQ

蛋白溶解后浓度偏低，如何调整？

低速离心：12,000 rpm, 5分钟，去除不溶物。缓冲液置换：使用超滤离心管（如10 kDa截留分子量）浓缩。
如何提高重组蛋白的可溶性表达？

可优化表达条件（如降低诱导温度、调整IPTG浓度）、使用促溶标签（如SUMO、GST）、共表达分子伴侣，或尝试不同宿主系统（如哺乳动物细胞或昆虫细胞）以提高可溶性蛋白产量。

推荐产品

400-621-6806
18630936064（微信同号）
周一至周五 8:30-18:00
0